United Therapeutics EVP & General Counsel Exercises Options and Sells Shares Under Rule 10b5-1 Plan

Executive Summary

On October 1, 2026, Paul A. Mahon, Executive Vice President & General Counsel of United Therapeutics Corp ($UTHR), executed an option exercise and subsequent sale of 8,300 shares of common stock. The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on August 11, 2025. Following the disposition, Mahon directly holds 45,172 shares of common stock.

Transaction Details

• Derivative Exercise: Exercised stock options for 8,300 shares at a strike price of $146.03 per share (total cost: $1,212,049.00). Post-exercise derivative holdings stood at 39,240 options.
• Sales: Disposed of all 8,300 acquired shares across 10 open-market tranches at prices ranging between $558.30 and $573.15 per share, yielding aggregate proceeds of approximately $4,694,907.03 (volume-weighted average price of ~$565.65 per share).
• Net Proceeds: Approximately $3,482,858.03 before taxes and fees.

Market Significance & Analysis

This transaction carries Low predictive significance regarding future share price performance. The sales were executed automatically under a Rule 10b5-1 trading plan adopted more than a year prior, representing routine equity compensation monetization and option expiration management rather than a discretionary trading decision based on material non-public information. Mahon maintains a substantial equity position of 45,172 direct shares plus 39,240 derivative options.